A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
Our aim was to determine the quantitative effects of a single-dose of Nattokinase (NK) administration on coagulation/fibrinolysis parameters comprehensively in healthy male subjects. A double-blind, placebo-controlled cross-over NK intervention study was carried out in 12 healthy young males. Following the baseline blood draw, each subject was randomized to receive either a single-dose of 2,000 FU NK (NSK-SD, Japan Bio Science Laboratory Co., Ltd) or placebo with subsequent cross-over of the groups. Subjects donated blood samples at 2, 4, 6 and 8 hours following administration for analysis of coagulation/fibrinolysis parameters. As a result, D-dimer concentrations at 6 and 8 hours and blood fibrin/fibrinogen degradation products at 4 hours after NK administration elevated significantly (p < 0.05, respectively). Factor VIII activity declined at 4 and 6 hours (p < 0.05, respectively), blood antithrombin concentration was higher at 2 and 4 hours (p < 0.05, respectively) and the activated partial thromboplastin time prolonged significantly at 2 and 4 hours following NK administration (p < 0.05 and p < 0.01, respectively). All the changes, however, were within the normal range. In conclusion, thus, a single-dose of NK administration appears enhancing fibrinolysis and anti-coagulation via several different pathways simultaneously.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Anti-thrombotic and anti-hypertensive activities of nattokinase have been demonstrated in small RCTs in humans [127,128].”
From Fermented foods: definitions and characteristics, impact on the gut microbiota and effects on gastrointestinal health and disease (2019) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sumi, H., Hamada, H., Tsushima, H., Mihara, H., & Muraki, H. (1987) · Experientia · doi:10.1007/bf01956052 · Cited by 570
Diabetes mellitus as a prothrombotic condition
Grant, P. J. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01824.x · Cited by 443
Stahl, M. L., & Ferrari, E. (1984) · Journal of Bacteriology · doi:10.1128/jb.158.2.411-418.1984 · Cited by 309
Fujita, M., Nomura, K., Hong, K., Ito, Y., Asada, A., & Nishimuro, S. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2624 · Cited by 306
Enhancement of the Fibrinolytic Activity in Plasma by Oral Administration of Nattokinases
Sumi, H., Hamada, H., Nakanishi, K., & Hiratani, H. (1990) · Acta Haematologica · doi:10.1159/000205051 · Cited by 304
Inflammation, sepsis, and coagulation.
Esmon, C. T., Fukudome, K., Mather, T., Bode, W., Regan, L. M., Stearns-Kurosawa, D. J., & Kurosawa, S. (1999) · PubMed · Cited by 252
Butenas, S., Mann, K. G., & Butenas (2002) · Biochemistry (Moscow) · doi:10.1023/a:1013985911759 · Cited by 203
Urano, T., Ihara, H., Umemura, K., Suzuki, Y., Oike, M., Akita, S., Tsukamoto, Y., Suzuki, I., & Takada, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101751200 · Cited by 167
Thrombolytic Effect of Nattokinase on a Chemically Induced Thrombosis Model in Rat.
FUJITA, M., HONG, K., ITO, Y., FUJII, R., KARIYA, K., & NISHIMURO, S. (1995) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.18.1387 · Cited by 147
Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons.
Taylor, F. B., Emerson, T. E., Jordan, R. E., Ak, C., & Blick, K. E. (1988) · PubMed · Cited by 144
Research works printed but not linked: 1
- Fukuda, S., Matsui, T., Tachibana, H., Tomoda, T. & Ohsugi, M. Development of functional soybean foods produced by fermentation with mushroom mycelia. Bull Mukogawa Women’s Univ Nat Sci. 55, 53–59 (2007).
Cited by
Items 101–115 of 115
UJI AKTIVITAS TROMBOLITIK EKSTRAK ETANOL RIMPANG TEMULAWAK SECARA IN VITRO
Hardini, K. R., Nurhayati, E., & Wahdaniah, W. (2019) · Jurnal Laboratorium Khatulistiwa · doi:10.30602/jlk.v3i1.930
Aspergillus tabacinus as a producer of antithrombotic proteases
Lavrenova, V. N., & Osmolovskiy, A. A. (2024) · Микология и фитопатология · doi:10.31857/s0026364824010022
Ramanathan, M., Madathil, M. J. K., Jose, J. M., & Ganesan, N. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249314623240923092315
Effectiveness of Treatments for Long Vax: Protocol for a Prospective Cohort Study (Preprint)Preprint
Halma, M. T. J. (2024) · doi:10.2196/preprints.70342
Recent Advances in Fermented Functional Foods
Mohedano, M. L., Zarour, K., Diez‐Ozaeta, I., Dueñas, M. T., López, P., & Russo, P. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837673292-00030 · Cited by 1
Allergy-induced acute coronary syndrome
Pereverzeva, K. G. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133326
Type I Kounis syndrome developing following administration of a plasma substitute (a clinical case)
Kozhevnikova, E., Pereverzeva, K. G., Gurbanova, A. A., & Yаkushin, S. S. (2025) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2025-3164
Gigineishvili, L. R., Fain, A. M., Starodubova, A. V., & Александровна, Р. А. (2025) · Russian Sklifosovsky Journal Emergency Medical Care · doi:10.23934/2223-9022-2025-14-3-601-608
Additional file 1 of Safety assessment of subtilisin QK in rats
Xiao, S., Hu, D., Gao, Y., Ai, Y., Luo, S., Chen, S., Wang, B., Zhou, L., Dong, Y., & Wang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14850622
Druzhinina, A. A., Gyulakhmedova, S. M., Alyautdina, O. S., Bashokouh, F., Eliseeva, E. M., & Chistokhina, A. A. (2026) · Avicenna Bulletin · doi:10.25005/2074-0581-2026-28-1-122-139
“…у матери увеличивала риск преждев - ременных родов, кесарева сечения, рождения крупных для ге - стационного возраста младенцев, госпитализации в отделение интенсивной терапии новорождённых, неонатальной гипоглике - мии, гипербилирубинемии, гипертензии, и врождённых пороков развития [3, 60-62].”
Potential Therapy for Long COVID and Post-vaccination Syndrome
Turčić, M., Pavelić, S. K., & Pavelić, K. (2026) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-032-06531-5_41
Advances in Nattokinase Research: Therapeutic Potential and Applications
Li, M., Wang, P., CHENG, M., Deng, X., Xizhong, S. O. N. G., & Weng, M. (2026) · Wuhan University Journal of Natural Sciences · doi:10.1051/wujns/2026312166
Degradation mechanism of the von Willebrand factor A2 domain by nattokinase
Hyakumoto, R., So, M., Furukawa, A., & Sugase, K. (2026) · FEBS Letters · doi:10.1002/1873-3468.70366
A Silica‐Based Molecularly Imprinted Polymer for the Specific Purification of Nattokinase
Dong, K., Xie, W., Zhang, Y., Zhou, G., & Liu, G. (2026) · Journal of Applied Polymer Science · doi:10.1002/app.71280
Metadata
- Authors
- Kurosawa, Y., Nirengi, S., Homma, T., Esaki, K., Ohta, M., Clark, J. F., & Hamaoka, T.
- Affiliations
- Ritsumeikan University (JP)
- Shunan University (JP)
- Kobe Pharmaceutical University (JP)
- University of Cincinnati (US)
- Corresponding author
- Hamaoka, Takafumi
- Venue
- Scientific Reports
- Published
- 2015-06-25
- Volume
- 5
- Issue
- 1
- Pages
- 11601-11601
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4479826
- OpenAlex
- W2404423380
- Cited by
- 115
- References
- 21
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 18 · 2023: 16 · 2022: 12 · 2021: 16 · 2020: 6 · 2019: 12 · 2018: 5 · 2017: 8 · 2016: 3
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Cincinnati
- Japan Society for the Promotion of Science (26350824)
- Topics
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Blood properties and coagulation
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- nattokinase, fibrinolysis, coagulation, thrombolysis, anticoagulation, D-dimer, fibrin/fibrinogen degradation products, factor VIII, antithrombin III, activated partial thromboplastin time, single-dose administration, healthy men
- MeSH terms
- Antithrombins, Blood Coagulation, Blood Coagulation Tests, Double-Blind Method, Factor VIII, Fibrin, Fibrin Fibrinogen Degradation Products, Fibrinogen, Fibrinolysis, Fibrinolytic Agents, Humans, Male, Partial Thromboplastin Time, Subtilisins, Time Factors, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.